IN8Bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid tumors, leukemia, and autoimmune diseases using its proprietary DeltEx™ platform. The company is pre-revenue, with lead programs in Phase 1 and Phase 2 oncology trials.
- Company typePublic
- Founded2016
- HeadquartersNew York, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What IN8Bio does
IN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in New York, with research operations in Birmingham, Alabama. The company develops gamma-delta T cell therapies for the treatment of solid and hematological malignancies, and is pursuing adjacent indications in autoimmune disease. Its core technology is the proprietary DeltEx™ platform, which spans four modalities: DeltEx DRI (genetically modified gamma-delta T cells engineered to resist chemotherapy), DeltEx Allo (donor-derived allogeneic cells for leukemia patients undergoing HSCT), DeltEx nsCAR-T (non-signaling CAR constructs that exploit natural gamma-delta T cell killing pathways), and iPSC-derived gamma-delta T cells enabling off-the-shelf products. The clinical pipeline includes INB-400 (Phase 2 newly diagnosed glioblastoma), INB-200 (Phase 1 newly diagnosed glioblastoma), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical assets INB-300 nsCAR-T, INB-500 iPSC gamma-delta T cells, and INB-619, a gamma-delta T cell engager for autoimmune disease.
IN8bio was the first company to bring genetically modified gamma-delta T cells into the clinic and reports differentiated efficacy signals: 13.0-month median progression-free survival versus 6.6-month standard of care in newly diagnosed GBM, 43% 24-month survival versus 20% for standard-of-care in repeat-dose GBM patients, and 100% complete remission with one-year PFS/OS in INB-100 AML patients (median follow-up 20.1 months), with 30% of those patients surviving beyond three years. The company is led by co-founders William Ho (CEO) and Dr. Lawrence Lamb (CSO), with Kate Rochlin, Ph.D., serving as President and COO, and Patrick McCall as CFO. The board underwent restructuring in February 2026 with Jeremy Graff appointed as Interim Chair.
The business model is pre-commercial: IN8bio generates no product revenue today and will commercialize through FDA-approved cell therapies administered at specialty treatment centers, with future distribution through specialty pharmacy networks. Pricing is undisclosed and will be set upon regulatory approval. The company is funded by equity capital markets rather than operating cash flow, having raised cumulatively more than $130M through a 2019 Series B, a 2022 public offering, and 2023-2025 private placements led by Coastlands Capital. Its go-to-market motion is enterprise/clinical, focused on executing FDA-regulated clinical trials at academic medical centers including O'Neal Comprehensive Cancer Center at UAB, University of Kansas Cancer Center, Ohio State University, and Dana-Farber Cancer Institute.
IN8Bio firmographics
Firmographics- Name
- IN8Bio
- Legal name
- IN8bio, Inc.
- Website
- https://in8bio.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell therapies for solid tumors, leukemia, and autoimmune diseases using its proprietary DeltEx™ platform. The company is pre-revenue, with lead programs in Phase 1 and Phase 2 oncology trials.
- Ownership category
- akta.pro rank
IN8Bio industry classification
Industry- Product category
- Cell Therapy / Immuno-oncology Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO), Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
Keywords
Where IN8Bio is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
IN8Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue will be generated through commercialization of FDA-approved gamma-delta T cell therapies for cancer treatment once clinical trials are successfully completed and regulatory approvals are obtained.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
IN8Bio product offering
Product offeringCore offering
IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases, built on its proprietary DeltEx™ platform that encompasses autologous, allogeneic, iPSC-derived, and genetically modified (DRI, nsCAR) approaches. Lead product candidates include INB-400 (Phase 2 GBM), INB-200 (Phase 1 GBM), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical INB-300 (nsCAR-T) and INB-619 (T cell engager for autoimmune disease).
Product overview
IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for cancer and autoimmune diseases. The company's DeltEx™ platform encompasses multiple technology approaches including DeltEx™ DRI (Drug Resistant Immunotherapy), DeltEx™ Allo (allogeneic), DeltEx™ DRI Auto (autologous), DeltEx™ nsCAR-T (non-signaling CAR), and iPSC-derived gamma-delta T cells. The clinical pipeline includes INB-400 (Phase 2, newly diagnosed GBM), INB-200 (Phase 1, newly diagnosed GBM), and INB-100 (Phase 1, acute leukemia/HSCT), while preclinical programs include INB-300/nsCAR-T platform and INB-619 T cell engager for autoimmune diseases. The company was the first to bring genetically modified gamma-delta T cells into the clinic.
Differentiator
Problem solved
Functional benefit
Brands
- DeltEx: IN8bio's proprietary platform technology for gamma-delta T cell therapies including DeltEx DRI (Drug Resistant Immunotherapy), DeltEx Allo, DeltEx DRI Auto, DeltEx nsCAR-T, and iPSC Gamma-Delta T Cells.
- DeltEx DRI
- DeltEx nsCAR-T
Products and services
- INB-200 (DeltEx DRI Auto) Genetically modified autologous gamma-delta T cell product candidate for newly diagnosed glioblastoma (GBM) solid tumors. Engineered to be resistant to alkylating chemotherapy such as temozolomide, enabling concomitant delivery with standard-of-care to maximize tumor killing during chemotherapy-induced stress. The first genetically engineered gamma-delta T cell therapy administered to patients.
- INB-100 (DeltEx Allo) Allogeneic gamma-delta T cell therapy product candidate for patients with acute leukemia undergoing hematopoietic bone marrow transplantation (HSCT). Provides donor-derived allogeneic gamma-delta T cells to patients post-HSCT to maintain remission and prevent relapse, addressing the approximately 50% relapse rate at 12 months post-transplant.
- INB-400 (DeltEx DRI Auto and Allo) Phase 2 product candidate for newly diagnosed glioblastoma (GBM) assessing both autologous and allogeneic genetically modified chemotherapy-resistant gamma-delta T cells. Engineered to be resistant to alkylating chemotherapy so it can be used in combination with the standard-of-care temozolomide (TMZ).
- INB-300 (DeltEx nsCAR-T) DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including INB-330 targeting CD-33 for AML. The nsCAR constructs lack signaling domains, taking advantage of gamma-delta T cells' natural properties to differentiate between healthy and tumor tissues; the CAR enhances tumor cell targeting while killing only occurs through natural gamma-delta T cell pathways that respond to cellular stress.
- INB-500 (iPSC Gamma-Delta T Cells) iPSC-derived gamma-delta T cell product candidate developed using cell-type specific differentiation processes. IN8bio was the first company to demonstrate the ability to generate both iPSC-derived Vd1+ and Vd2+ gamma-delta T cell subtypes. iPSC-derived gamma-delta cells address donor sourcing and manufacturing expansion limitations, offering potential off-the-shelf therapeutic products.
- INB-619 (Gamma-Delta T Cell Engager) Next-generation gamma-delta T cell engager (TCE) platform for autoimmune diseases. Preclinical data presented at the 2025 American College of Rheumatology Conference demonstrated deep B cell depletion with a potentially improved safety profile compared to existing autoimmune therapies. IND-enabling studies are progressing with initial animal data expected in 2026.
Quantifiable outcome
- 97% improvement in median progression-free survival (13.0 months vs 6.6 months standard-of-care) in newly diagnosed GBM patients
- +3 more outcomes
Companies that use IN8Bio
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
IN8Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
IN8Bio partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered supporting and core.
- Dana-Farber Cancer InstitutesupportingDr. David Reardon from Dana-Farber Cancer Institute provides clinical perspective on IN8bio's DeltEx DRI therapy program at R&D Day and medical conferences.
- The Ohio State UniversitycoreAdded as a new clinical trial site for INB-100 Phase 1 trial evaluating gamma-delta T cell therapy for leukemia patients undergoing hematopoietic stem cell transplantation. Selected for transplant expertise and operational excellence.
- O'Neal Comprehensive Cancer Center at University of Alabama at BirminghamcoreClinical trial site for INB-200 Phase 1 repeat dose escalation trial for newly diagnosed glioblastoma patients.
- University of Kansas Cancer CentercoreClinical trial site for INB-100 Phase 1 dose escalation trial for acute leukemia patients undergoing hematopoietic bone marrow transplantation.
Scale indicators15 records
Recent moves6 records
Expansion highlights5 records
IN8Bio competitors and assessment
Company assessmentDirect peers
- Adicet Bio: Direct competitor developing allogeneic gamma-delta T cell therapies for both oncology and autoimmune disease, overlapping directly with IN8Bio's DeltEx Allo and INB-619 programs. Both companies are pursuing off-the-shelf gamma-delta T cell approaches with significant autoimmune disease focus.
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered T cell therapies (SPEAR T-cells) for solid tumors. Direct comparable given its focus on cell-based oncology therapeutics and similar clinical-stage profile.
- Allogene Therapeutics: Clinical-stage company developing allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors. Highly comparable given the shared allogeneic cell therapy modality and oncology focus.
- Fate Therapeutics: Clinical-stage company developing iPSC-derived off-the-shelf NK and T cell therapies for cancer and autoimmune disease. Closely comparable to IN8Bio's INB-500 iPSC gamma-delta T cell program in both modality and off-the-shelf positioning.
- Century Therapeutics: Clinical-stage company developing iPSC-derived allogeneic cell therapies including gamma-delta T cells and NK cells. Direct comparable given iPSC-derived platform approach and similar early-stage clinical profile.
- Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a clinical-stage cell therapy peer with similar allogeneic platform positioning.
- TC BioPharm: Clinical-stage company developing gamma-delta T cell therapies for cancer and viral infections. Direct peer in the gamma-delta T cell space, addressing overlapping indications and mechanisms.
- Cellectis: Clinical-stage gene-edited allogeneic CAR-T cell therapy company with TALEN-based platform. Comparable in allogeneic cell therapy approach and gene-editing modality, with multiple oncology programs in clinical development.
Broad incumbents
- Iovance Biotherapeutics: Larger, more advanced cell therapy company with FDA-approved TIL therapy (lifileucel) for solid tumors. Comparable in cell therapy approach to solid tumors, with a much later commercial stage that highlights both the opportunity and the gap to bridge for IN8Bio.
- CRISPR Therapeutics: Larger gene-edited cell therapy company with approved CASGEVY for sickle cell disease. Comparable in cell therapy modality and oncology/hematology focus, with significantly greater financial resources and commercial-stage experience.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
IN8Bio social profiles
Digital presenceIN8Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
IN8Bio leadership team
Management profileNumber of profiles
Profiles6 records
IN8Bio funding detail
Funding detailFunding overview
Funding rounds6 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IN8Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IN8Bio
What does IN8Bio do?
IN8Bio is a clinical-stage biopharmaceutical company developing a portfolio of gamma-delta T cell therapies for solid tumors, hematologic malignancies, and autoimmune diseases, built on its proprietary DeltEx™ platform that encompasses autologous, allogeneic, iPSC-derived, and genetically modified (DRI, nsCAR) approaches. Lead product candidates include INB-400 (Phase 2 GBM), INB-200 (Phase 1 GBM), and INB-100 (Phase 1 acute leukemia/HSCT), with preclinical INB-300 (nsCAR-T) and INB-619 (T cell engager for autoimmune disease).
Is IN8Bio a public or private company?
IN8Bio is a public company. It is classified as public and is currently operating.
When was IN8Bio founded?
IN8Bio was founded in 2016. It employs 11 to 50 people.
Where is IN8Bio based?
IN8Bio is headquartered in New York, United States, in the North America region.
How does IN8Bio make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are IN8Bio's main competitors?
Direct peers on record are Adicet Bio, Adaptimmune Therapeutics, Allogene Therapeutics, Fate Therapeutics, Century Therapeutics, Caribou Biosciences, TC BioPharm and Cellectis. Broad incumbents are Iovance Biotherapeutics and CRISPR Therapeutics.
Does IN8Bio have an API?
No public API is recorded for IN8Bio.
What industry is IN8Bio in?
IN8Bio's product category is Cell Therapy / Immuno-oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325414 and its SIC code is 2836.